201 related articles for article (PubMed ID: 29862563)
41. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract][Full Text] [Related]
42. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
Luna DE; Shinohara MM
Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
[TBL] [Abstract][Full Text] [Related]
43. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides.
Chong BF; Wilson AJ; Gibson HM; Hafner MS; Luo Y; Hedgcock CJ; Wong HK
Clin Cancer Res; 2008 Feb; 14(3):646-53. PubMed ID: 18245523
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
Leroy S; Dubois S; Tenaud I; Chebassier N; Godard A; Jacques Y; Dréno B
Br J Dermatol; 2001 May; 144(5):1016-23. PubMed ID: 11359391
[TBL] [Abstract][Full Text] [Related]
45. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
46. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
47. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas.
Lu D; Patel KA; Duvic M; Jones D
J Cutan Pathol; 2002 Sep; 29(8):465-72. PubMed ID: 12207740
[TBL] [Abstract][Full Text] [Related]
48. Phenotypic characterization of skin-infiltrating T cells in cutaneous T-cell lymphoma: comparison with benign cutaneous T-cell infiltrates.
Haynes BF; Hensley LL; Jegasothy BV
Blood; 1982 Aug; 60(2):463-73. PubMed ID: 7046848
[TBL] [Abstract][Full Text] [Related]
49. Myocosis fungoides--an update on a non-mycotic disease.
Makdisi J; Friedman A
J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
[TBL] [Abstract][Full Text] [Related]
50. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma.
Jackow CM; McHam JB; Friss A; Alvear J; Reveille JR; Duvic M
J Invest Dermatol; 1996 Sep; 107(3):373-6. PubMed ID: 8751973
[TBL] [Abstract][Full Text] [Related]
51. Immunocytochemical characterisation of cutaneous lymphomas other than mycosis fungoides.
Ralfkiaer E; Saati TA; Bosq J; Delsol G; Gatter KC; Mason DY
J Clin Pathol; 1986 May; 39(5):553-63. PubMed ID: 3522633
[TBL] [Abstract][Full Text] [Related]
52. Mycosis fungoides/Sézary syndrome: report of an unusual case.
Mehta A; Dhungel BM; Khan MF
J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
[TBL] [Abstract][Full Text] [Related]
53. A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS.
Mao X; Orchard G; Mitchell TJ; Oyama N; Russell-Jones R; Vermeer MH; Willemze R; van Doorn R; Tensen CP; Young BD; Whittaker SJ
J Cutan Pathol; 2008 Oct; 35(10):899-910. PubMed ID: 18494816
[TBL] [Abstract][Full Text] [Related]
54. Determination of T-cell clonality and expression profiles of Toll-like receptors signaling pathway genes and related miRNAs in patients with mycosis fungoides.
Seçme M; Dodurga Y; Demirkan NÇ; Kaçar N; Günel NS; Açıkbaş İ
Gene; 2024 Jan; 891():147825. PubMed ID: 37748629
[TBL] [Abstract][Full Text] [Related]
55. Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome.
Quaglino P; Fava P; Pileri A; Grandi V; Sanlorenzo M; Panasiti V; Guglielmo A; Alberti-Violetti S; Novelli M; Astrua C; Rubatto M; Tonella L; Berti E; Pimpinelli N; Osella Abate S; Fierro MT; Vermeer M; Scarisbrick JJ; Ribero S
J Invest Dermatol; 2021 Mar; 141(3):484-495. PubMed ID: 33162051
[TBL] [Abstract][Full Text] [Related]
56. Genotyping of cutaneous T-cell lymphomas and pseudolymphomas.
Bignon YJ; Souteyrand P
Curr Probl Dermatol; 1990; 19():114-23. PubMed ID: 2404672
[No Abstract] [Full Text] [Related]
57. Interleukin-7 receptor expression in cutaneous T-cell lymphomas.
Bagot M; Charue D; Boulland ML; Gaulard P; Revuz J; Schmitt C; Wechsler J
Br J Dermatol; 1996 Oct; 135(4):572-5. PubMed ID: 8915148
[TBL] [Abstract][Full Text] [Related]
58. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
Harmon CB; Witzig TE; Katzmann JA; Pittelkow MR
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):404-10. PubMed ID: 8784277
[TBL] [Abstract][Full Text] [Related]
59. CD44 variant expression in cutaneous T-cell lymphoma.
Orteu CH; Li W; Allen MH; Smith NP; Barker JN; Whittaker SJ
J Cutan Pathol; 1997 Jul; 24(6):342-9. PubMed ID: 9243361
[TBL] [Abstract][Full Text] [Related]
60. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
